Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640447 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTEPHX2CNR1CNR2 | |
| SCHEMBL19640541 | 0.86 | ALDH1A1 (0.38) | ALDH1A1MAPTEPHX2CNR1CNR2 | |
| SCHEMBL19640543 | 0.86 | ALDH1A1 (0.38) | ALDH1A1MAPTEPHX2CNR1CNR2 | |
| SCHEMBL19640383 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTCNR1CNR2ALOX12 | |
| SCHEMBL17790863 | 0.79 | CNR1 (0.50) | ALDH1A1MAPTEPHX2CNR1CNR2 | |
| SCHEMBL19651562 | 0.74 | EHMT2 (0.40) | ALDH1A1MAPTHDAC1HDAC2SMN1; SMN2 | |
| SCHEMBL19640751 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPTCNR1CNR2ALOX12 | |
| SCHEMBL19640752 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPTCNR1CNR2ALOX12 | |
| SCHEMBL19640404 | 0.72 | SREBF2 (0.51) | ALDH1A1MAPTEPHX2FAAHHDAC1 | |
| SCHEMBL19640405 | 0.72 | SREBF2 (0.51) | ALDH1A1MAPTEPHX2FAAHHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | ALDH1A1 1220/4885MAPT 867/4885EPHX2 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.